Text Size
A A A
Skip Navigation

Home > RePORTER > Project Information

Project InformationProject Information Help

Project Number: 1U01NS074501-01 Contact PI / Project Leader: WAGNER, STEVEN LEE
Title: OPTIMIZATION OF SOLUBLE GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER Awardee Organization: UNIVERSITY OF CALIFORNIA AT SAN DIEGO
Description
Abstract Text:
DESCRIPTION (provided by applicant): The broad goals of our project are to pharmacologically optimize, mechanistically characterize (in the most appropriate molecular, cellular and transgenic animal models) and complete the entire preclinical development (through IND filing) of a potent orally bioavailable therapeutic compound carefully selected from a novel series of recently discovered gamma-secretase modulators (GSMs) for the treatment of Alzheimer's disease (AD). AD is neurodegenerative disorder that affects regions of the brain associated with learning and memory. AD affects over 24 million people world-wide and is an enormous burden to society. The extent at which it will affect our aging population will continue to escalate. A recently discovered a series of aryl 2-aminothiazole gamma-secretase modulators (AGSMs) that are pharmaceutical-like small organic molecules that are able to lower Abeta42 production without measurably affecting -Secretase-mediated enzymatic processing of other known gamma-secretase substrates such as the Notch-1 receptor. This project will focus on the pharmacological optimization of a series of AGSMs with improved physicochemical properties known as SGSMs. If successful in a number of predictive preclinical studies, these molecules will undergo further IND-enabling preclinical development and ultimately be tested in humans. PUBLIC HEALTH RELEVANCE: Alzheimer's disease is a major neurodegenerative disease that affects over 24 million people world-wide and currently there is no known cure. This disease if left without an appropriate intervening therapeutic will devastate our Healthcare systems.
Public Health Relevance Statement:
Alzheimer's disease is a major neurodegenerative disease that affects over 24 million people world-wide and currently there is no known cure. This disease if left without an appropriate intervening therapeutic will devastate our Healthcare systems.
NIH Spending Category:
Aging; Alzheimer's Disease; Brain Disorders; Neurodegenerative; Neurosciences
Project Terms:
Acetylcholinesterase Inhibitors; Acute; Affect; Age; aging population; Alzheimer's Disease; Amino Acids; Amyloid; Amyloid beta-Protein; Amyloid beta-Protein Precursor; analog; Animal Model; aqueous; base; Behavioral; Bioavailable; Biochemical; Biological Testing; Brain; Brain region; Caregivers; Cerebrum; Chemical Structure; Chronic; Clinical; Development; Diffuse; Disease; Disease Progression; Dose; Drug Formulations; Elderly; Family member; Funding; gamma secretase; Goals; Healthcare Systems; Human; improved; In Vitro; Investigational Drugs; Lead; Learning; Left; Mediating; meetings; Memory; Molecular; mouse model; Neurodegenerative Disorders; Neurofibrillary Tangles; Neurons; notch protein; novel; Oral Administration; Parents; Pathogenesis; Patients; Peptides; Pharmaceutical Chemistry; Pharmacologic Substance; Phase; Plasma; pre-clinical; preclinical study; Preclinical Testing; prevent; Process; Prodrugs; Production; Property; Proteolytic Processing; Reagent; receptor; Regimen; Research; secretase; Senile Plaques; Series; Site; Societies; Solubility; Structure-Activity Relationship; Testing; Therapeutic; Toxic effect; Transgenic Animals; Transgenic Mice; Work



The RePORTER database is available to all public users at http://exporter.nih.gov/. As the data are available for bulk download, the RePORTER system reserves the right to block IP addresses that fail to adhere to instructions in the system’s robots.txt files or submit requests at a rate that negatively impacts service delivery to other users. RePORTER reserves the right to terminate any automated query to the RePORTER application that negatively affects service delivery to other users.

Page Last Updated on March 18, 2013
This site is best viewed with Internet Explorer (7.0 or higher) or Mozilla Firefox (3.0).

NIH...Turning Discovery Into Health®
RePORTERE3